Metabolic tumor volume on FDG-PET/CT is a possible prognostic factor for Stage I lung cancer patients treated with stereotactic body radiation therapy: a retrospective clinical study

被引:18
作者
Takahashi, Noriyoshi [1 ]
Yamamoto, Takaya [1 ]
Matsushita, Haruo [1 ]
Sugawara, Toshiyuki [1 ]
Kubozono, Masaki [1 ]
Umezawa, Rei [1 ]
Ishikawa, Yojiro [1 ]
Kozumi, Maiko [1 ]
Katagiri, Yu [1 ]
Tasaka, Syun [1 ]
Takeda, Kazuya [1 ]
Takeda, Ken [2 ]
Dobashi, Suguru [2 ]
Jingu, Keiichi [1 ]
机构
[1] Tohoku Univ, Dept Radiat Oncol, Grad Sch Med, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan
[2] Tohoku Univ, Sch Hlth Sci, Dept Radiol Technol, Fac Med,Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan
关键词
stereotactic body radiation therapy; non-small cell lung cancer; NSCLC; metabolic tumor volume; total lesion glycolysis; prognostic factor; STANDARDIZED UPTAKE VALUE; LOCAL-CONTROL; RADIOTHERAPY; PRETREATMENT; PREDICTOR; OUTCOMES;
D O I
10.1093/jrr/rrw048
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The aim of this study was to determine whether metabolic tumor volume (MTV) and total lesion glycolysis (TLG) are associated with outcomes in Stage I lung cancer patients treated with stereotactic body radiation therapy (SBRT). Thirty-eight patients underwent [F-18] fluorodeoxyglucose positron emission tomography/computed tomography (F-18-FDG-PET/CT) within 60 days before SBRT at our institution between January 2001 and December 2011. The maximum standardized uptake value (SUVmax), MTV2, MTV4, MTV6, TLG(40%), TLG(50%) and TLG(60%) were calculated. Prognostic factors for overall survival (OS) and local control (LC) were analyzed using Cox's proportional hazards model, and survival curves were calculated using the Kaplan-Meier method. Receiver operating characteristics (ROC) curves of PET parameters for OS and LC were calculated. The median follow-up period for survivors was 37.7 months. Three-year OS and LC rates were 56.4% and 70.5%, respectively, and 5-year OS and LC rates were 36.8% and 70.5%, respectively. In univariate analyses, tumor diameter (P = 0.019), single dose >= 10 Gy (P = 0.017), MTV2 (P = 0.030) and MTV4 (P = 0.048) were significant predictors for OS. Tumor diameter (P < 0.001), single dose = 10 Gy (P = 0.007), SUVmax (P = 0.035), MTV2 (P < 0.001), MTV4 (P = 0.003), MTV6 (P = 0.017), TLG(40%) (P < 0.001), TLG(50%) (P = 0.001) and TLG(60%) (P = 0.003) were significant predictors for LC. SUVmax was not a significant predictor for OS. We made the ROC curves at PET parameters, and the largest area under the curve value for OS was MTV2 and for LC was TLG(40%). Tumor diameter, single dose >= 10 Gy, MTV2 and MTV4 are prognostic factors for OS and LC rates and MTV2 is a better prognostic factor for OS than other PET parameters.
引用
收藏
页码:655 / 661
页数:7
相关论文
共 17 条
  • [1] Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy
    Abelson, Jonathan A.
    Murphy, James D.
    Trakul, Nicholas
    Bazan, Jose G.
    Maxim, Peter G.
    Graves, Edward E.
    Quon, Andrew
    Quynh-Thu Le
    Diehn, Maximilian
    Loo, Billy W., Jr.
    [J]. LUNG CANCER, 2012, 78 (03) : 219 - 224
  • [2] MAXIMUM STANDARDIZED UPTAKE VALUE FROM STAGING FDG-PET/CT DOES NOT PREDICT TREATMENT OUTCOME FOR EARLY-STAGE NON SMALL-CELL LUNG CANCER TREATED WITH STEREOTACTIC BODY RADIOTHERAPY
    Burdick, Michael J.
    Stephans, Kevin L.
    Reddy, Chandana A.
    Djemil, Toufik
    Srinivas, Shyam M.
    Videtic, Gregory M. M.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 78 (04): : 1033 - 1039
  • [3] Esfahani SA, 2013, AM J NUCL MED MOLEC, V3, P272
  • [4] STEREOTACTIC BODY RADIATION THERAPY FOR EARLY-STAGE NON-SMALL-CELL LUNG CARCINOMA: FOUR-YEAR RESULTS OF A PROSPECTIVE PHASE II STUDY
    Fakiris, Achilles J.
    McGarry, Ronald C.
    Yiannoutsos, Constantin T.
    Papiez, Lech
    Williams, Mark
    Henderson, Mark A.
    Timmerman, Robert
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (03): : 677 - 682
  • [5] Relationship between Pretreatment FDG Uptake and Local Control after Stereotactic Body Radiotherapy in Stage I Non-small-cell Lung Cancer: The Preliminary Results
    Hamamoto, Yasushi
    Sugawara, Yoshifumi
    Inoue, Takeshi
    Kataoka, Masaaki
    Ochi, Takashi
    Takahashi, Tadaaki
    Sakai, Shinya
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2011, 41 (04) : 543 - 547
  • [6] FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer
    Hoopes, David J.
    Tann, Mark
    Fletcher, James W.
    Forquer, Jeffrey A.
    Lin, Pei-Fen
    Lo, Simon S.
    Timmerman, Robert D.
    McGarry, Ronald C.
    [J]. LUNG CANCER, 2007, 56 (02) : 229 - 234
  • [7] Jingu K, 2014, J RADIOL RAD THER, V2, P1041
  • [8] Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame
    Nagata, Y
    Takayama, K
    Matsuo, Y
    Norihisa, Y
    Mizowaki, T
    Sakamoto, T
    Sakamoto, M
    Mitsumori, M
    Shibuya, K
    Araki, N
    Yano, S
    Hiraoka, M
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2005, 63 (05): : 1427 - 1431
  • [9] Pretreatment [18F]-fluoro-2-deoxy-glucose Positron Emission Tomography Maximum Standardized Uptake Value as Predictor of Distant Metastasis in Early-Stage Non-Small Cell Lung Cancer Treated With Definitive Radiation Therapy: Rethinking the Role of Positron Emission Tomography in Personalizing Treatment Based on Risk Status
    Nair, Vimoj J.
    MacRae, Robert
    Sirisegaram, Abby
    Pantarotto, Jason R.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02): : 312 - 318
  • [10] Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: Updated results of 257 patients in a Japanese multi-institutional study
    Onishi, Hiroshi
    Shirato, Hiroki
    Nagata, Yasushi
    Hiraoka, Masahiro
    Fujino, Masaharu
    Gomi, Kotaro
    Niibe, Yuzuru
    Karasawa, Katsuyuki
    Hayakawa, Kazushige
    Takai, Yoshihiro
    Kimura, Tomoki
    Takeda, Atsuya
    Ouchi, Atsushi
    Hareyama, Masato
    Kokubo, Masaki
    Hara, Ryusuke
    Itami, Jun
    Yamada, Kazunari
    Araki, Tsutomu
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (07) : S94 - S100